Phase 1/2a, Randomized, Double-Blind Placebo-Controlled, Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Response of PB1023 Injection Following Single and Multiple Ascending Subcutaneous Doses in Adult Subjects With Type 2 Diabetes Mellitus (T2DM).
Phase of Trial: Phase I/II
Latest Information Update: 20 May 2013
At a glance
- Drugs PB 1023 (Primary)
- Indications Hyperglycaemia; Type 2 diabetes mellitus
- Focus Adverse reactions
- 07 Jun 2017 Biomarkers information updated
- 12 Jun 2012 Results of the phase IIa portion of this study (conducted in 54 patients) presented at the 72nd Annual Scientific Sessions of the American Diabetes Association.
- 15 Nov 2011 Status changed from active, no longer recruiting to completed, according to a PhaseBio Pharmaceuticals media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History